Cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal cells that can invade tissues and metastasize to distant organs.
Novartis acquires UK biotech Myricx Bio for up to $1.5B, gaining a novel NMTi ADC payload platform and two lead assets targeting B7-H3 and HER2. The deal includes $1.1B upfront with $400M in milestones, expected to close in H2 2026.
The FDA will allow food makers to claim "no artificial colors" as long as dyes are not petroleum-based, even if products contain titanium dioxide. Health experts warn the labeling deceives consumers, as naturally derived additives like titanium dioxide pose health risks and remain unregulated.
Bayer outlined its 2030 growth strategy at Pharma Media Day 2026, driven by AI partnerships, precision medicine, and a strengthened pipeline. The company aims for mid-single-digit growth from 2027 and 30% margins by 2030.
The U.S. five-year cancer survival rate reached 70% in 2025, creating 18.6 million survivors. Health systems are expanding survivorship care using advanced practice providers and investing over $4 billion in oncology infrastructure to meet growing demand.
Scientists have identified SLAMF6 as a key suppressor of T cell immunity against cancer and developed monoclonal antibodies that neutralize it in mice, published in Nature. Biotechnology company Replimune Group has reported its 2026 financial position, with a market value of approximately $234.5 million and ongoing clinical trials.
Research has identified CD27 expression as a potential biomarker for monitoring regulatory T cell (Treg) induction efficacy in clinical trials. Studies show CD27 marks memory-like Tregs with superior suppressive capacity, correlating with immune regulation in type 1 diabetes patients. Treg-based tolerance restoration is emerging as a therapeutic strategy for autoimmune diseases and transplantation.
University of Alberta researchers have identified the protease GlpG as a new drug target for antibiotic-resistant E. coli, which causes hundreds of thousands of UTI deaths annually. Inhibiting GlpG prevented bacterial adhesion and biofilm formation in laboratory studies. The discovery addresses a global health emergency as antimicrobial resistance projections show it could cause cancer-level deaths by 2050.
Brazilian researchers developed a CT-based biomarker called VMD that combines visceral fat and muscle radiodensity to predict gastric cancer prognosis, with patient survival ranging from 13.8 to 58.5 months. The global PET imaging market is projected to grow to $1.4 billion by 2032 as cancer cases rise globally. Neuroendocrine tumor research is advancing with new funding and studies on Hedgehog signaling pathways.
New rankings from WIPR and IAM Patent 1000 recognize top US patent firms and lawyers, highlighting expertise in pharmaceutical litigation, tech disputes, and strategic portfolio management amid shifting PTAB procedures and rising NPE campaigns in life sciences.
The Fonds pour l'Innovation et le Futur de Genève (FIF) has awarded funding to six Geneva-based startups across two rounds, including Backbone, Crìa Technologies, Scenario X, Flottando, Axy, and Nose Switzerland, supporting innovations in AI, quantum computing, fleet management, and life sciences.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07612943 |
ProspectiveMaleAYA - Frequency and Prediction of Therapy-induced Testicular Dysfunction in AYA Cancer Survivors |
NOT_YET_RECRUITING | |
| NCT07609485 |
Identifying Cellular and Molecular Determinants of Efficacy and Resistance in Patients Undergoing CAR-T Therapy |
RECRUITING | |
| NCT07608848 |
First-in-human Imaging Study of Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low-dose [177Lu]Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic Cancer |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT07606313 |
Phase I Randomized Controlled Trial of Functional Resistance Training in Older Cancer Survivors: The ACES Trial |
NOT_YET_RECRUITING | NA |
| NCT07601802 |
Acute Risk Monitoring for Oncology Therapy Regimen |
COMPLETED | |
| NCT07600294 |
Integrated Cancer Services in Thailand: A Prototype for Excellence |
COMPLETED | NA |
| NCT07598851 |
Virtual Reality Education for Radiation Therapy Patients |
COMPLETED | NA |
| NCT07598747 |
Prospective Study for the Development, Validation and Confirmation of a Multi-Cancer Early Detection Platform Through Whole-Genome Sequencing Analysis of Circulating DNA in Cancer and Non-Cancer Subjects |
RECRUITING | |
| NCT07588607 |
Social Media Posts About Cancer: Five Timepoints |
COMPLETED | NA |
| NCT07585838 |
Hope-Focused Motivational Interviewing in Cancer Patients |
ENROLLING_BY_INVITATION | NA |
